Dixon Hughes Goodman Wealth Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Dixon Hughes Goodman Wealth Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$6K	Buy	+100	New	+$6.28K	﹤0.01%	571

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dixon Hughes Goodman Wealth Advisors's CRSP Position: Q1 2022 in Review

Dixon Hughes Goodman Wealth Advisors opened a new position in CRISPR Therapeutics (CRSP) in Q1 2022: 100 shares worth $6K. The stake represents ﹤0.01% of the portfolio and ranks #571 among its holdings.

447 funds tracked by Wall St. Rank hold CRSP as of Q1 2022.

Dixon Hughes Goodman Wealth Advisors held 100 shares of CRISPR Therapeutics worth $6K as of Q1 2022.
CRISPR Therapeutics was a new Dixon Hughes Goodman Wealth Advisors position in Q1 2022.
CRISPR Therapeutics made up ﹤0.01% of Dixon Hughes Goodman Wealth Advisors's portfolio in Q1 2022, its #571 holding.
447 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2022.

Based on Dixon Hughes Goodman Wealth Advisors's 13F filing for Q1 2022, filed 4 Apr 2022.